文献速递免疫规划传染病防控与疫情报告

HIV gp120-NefTat/AS01B疫苗接种后14年疫苗诱导免疫应答的持续性

Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination.
PubMed 文献 · Vaccine · 2020-01-10

本研究为单中心、开放标签、描述性I期延伸研究(NCT03368053),纳入14年前曾接种≥3剂B亚型gp120-NefTat/AS01B候选疫苗的成人。采用结合抗体多重检测法(BAMA)和胞内细胞因子染色法评估免疫应答持续性。结果显示,接种14年后仍可检测到针对多种HIV-1包膜糖蛋白的结合抗体及gp120特异性CD4+ T细胞应答,但未检测到CD8+ T细胞。

要点

  • 接种14年后,V1V2广度面板16种抗原中15种可检出阳性IgG结合抗体应答,阳性率为7.1%至60.7%。
  • gp120和gp140广度面板抗原应答率分别为7.7%至94.1%和15.4%至96.2%。
  • gp120特异性多功能CD4+ T细胞持续至第14年,但未检测到CD8+ T细胞。

核心结论

  • 在14年前接种gp120-NefTat/AS01B候选疫苗的志愿者中,观察到针对HIV-1包膜糖蛋白(包括V1V2支架)的持续结合抗体以及gp120特异性细胞免疫。

研究设计与样本

  • 本研究为单中心、开放标签、描述性I期延伸研究(NCT03368053),单组设计,纳入14年前在既往临床试验(NCT00434512)中接种≥3剂B亚型gp120-NefTat/AS01B候选疫苗的成人。
  • 采用结合抗体多重检测法(BAMA)检测针对一组包膜糖蛋白(包括gp120、gp140和V1V2支架抗原)的血清抗体结合应答,采用胞内细胞因子染色法评估gp120特异性CD4+/CD8+ T细胞应答。

主要发现

  • 第14年时,V1V2广度面板16种抗原中15种可检出阳性IgG结合抗体应答,阳性率为7.1%至60.7%,最高应答率见于B亚型毒株V1V2抗原,对C亚型毒株亦有一定水平结合抗体。
  • 抗V1V2 IgG3应答强度广度有限,该指标在既往效力试验中与感染风险降低相关。
  • 第14年时,gp120和gp140广度面板抗原的应答率分别为7.7%至94.1%和15.4%至96.2%。
  • 经gp120肽池刺激后,高度多功能的gp120特异性CD4+ T细胞持续至第14年,CD40L肿瘤坏死因子α(TNF-α)、CD40L白细胞介素-2(IL-2)、CD40L TNF-α IL-2及CD40L干扰素γ(IFN-γ)TNF-α IL-2 CD4+ T细胞频率较高,但未检测到CD8+ T细胞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccines eliciting protective and persistent immune responses against multiple human immunodeficiency virus type 1 (HIV-1) clades are needed. This study evaluated the persistence of immune responses induced by an investigational, AS01-adjuvanted HIV-1 vaccine as long as 14 years after vaccination. METHODS: This phase I, open-label, descriptive, mono-centric, extension study with a single group (NCT03368053) was conducted in adults who received ≥3 doses of the clade B gp120-NefTat/AS01B vaccine candidate 14 years earlier in a previous clinical trial (NCT00434512). Binding responses of serum antibodies targeting a panel of envelope glycoproteins, including gp120, gp140 and V1V2-scaffold antigens and representative of the antigenic diversity of HIV-1, were measured by binding antibody multiplex assay (BAMA). The gp120-specific CD4+/CD8+ T-cell responses were assessed by intracellular cytokine staining assay. RESULTS: At Year 14, positive IgG binding antibody responses were detected in 15 out of the 16 antigens from the BAMA V1V2 breadth panel, with positive response rates ranging from 7.1% to 60.7%. The highest response rates were observed for clade B strain V1V2 antigens, with some level of binding antibodies against clade C strains. Anti-V1V2 IgG3 response magnitude breadth, which correlated with decreased risk of infection in a previous efficacy trial, was of limited amplitude. Response rates to the antigens from the gp120 and gp140 breadth panels ranged from 7.7% to 94.1% and from 15.4% to 96.2% at Year 14, respectively. Following stimulation with gp120 peptide pool, highly polyfunctional gp120-specific CD4+ T-cells persisted up to Year 14, with high frequencies of CD40L tumor necrosis factor alpha (TNF-α), CD40L interleukin-2 (IL-2), CD40L TNF-α IL-2 and CD40L interferon gamma (IFN-γ) TNF-α IL-2 CD4+ T-cells, but no CD8+ T-cells detected. CONCLUSIONS: Persistent antibodies binding to HIV-1 envelope glycoproteins, including the V1V2-scaffold, and gp120-specific cellular immunity were observed in volunteers vaccinated 14 years earlier with the gp120-NefTat/AS01B vaccine candidate.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Van Der Meeren O, Jongert E, Seaton KE, et al. Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination. Vaccine. 2020. PMID: 31932137. doi:10.1016/j.vaccine.2019.12.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。